PYRIMIDONE DERIVATIVES AS SELECTIVE CYTOTOXIC AGENTS AGAINST HIV INFECTED CELLS

The present disclosure is directed to pyrimidone derivatives of Formula I and their use for selectively killing HIV infected GAG-POL expressing cells without concomitant cytotoxicity to HIV nave cells, and for the treatment or prophylaxis of infection by HIV, or for the treatment, prophylaxis or del...

Full description

Saved in:
Bibliographic Details
Main Authors FRIE, JESSICA L, HUNTER, DAVID N, MITCHELL, HELEN J, CONVERSO, ANTONELLA, SHA, DEYOU, FORSTER, ASHLEY, EL MARROUNI, ABDELLATIF, KUDUK, SCOTT D, WANG, CHENG, NANTERMET, PHILIPPE, SHIPE, WILLIAM DANIEL, WANG, DEPING
Format Patent
LanguageEnglish
French
Published 01.08.2023
Subjects
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:The present disclosure is directed to pyrimidone derivatives of Formula I and their use for selectively killing HIV infected GAG-POL expressing cells without concomitant cytotoxicity to HIV nave cells, and for the treatment or prophylaxis of infection by HIV, or for the treatment, prophylaxis or delay in the onset or progression of AIDS or AIDS Related Complex (ARC). La présente invention concerne des dérivés de pyrimidone de formule I et leur utilisation pour tuer sélectivement des cellules exprimant GAG-POL infectées par le VIH sans cytotoxicité concomitante vis-à-vis de cellules naïves du VIH, et pour le traitement ou la prophylaxie d'une infection par le VIH, ou pour le traitement, la prophylaxie ou le retardement de l'apparition ou de la progression du SIDA ou du complexe associé au SIDA (ARC).
Bibliography:Application Number: CA20193122571